Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Ventilation -18% Death/intubation -2% Discharge -2% Colchicine  RECOVERY  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 11,340 patients in the United Kingdom (November 2020 - March 2021) Higher ventilation with colchicine (not stat. sig., p=0.06) c19early.org Recovery Collaborative Group, The Lanc.., May 2021 Favors colchicine Favors control

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Recovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (date from preprint), RECOVERY, NCT04381936
May 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000056 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset, baseline 32% ventilation (5% invasive). ISRCTN 50189673.
Dose frequency was halved for patients receiving a moderate CYP3A4 inhibitor, patients with an estimated glomerular filtration rate of less than 30 mL/min per 1·73m², and those with an estimated bodyweight of less than 70kg.
This study is excluded in the after exclusion results of meta analysis: very late stage, 9 days since symptoms started, 32% baseline ventilation.
risk of death, 1.0% higher, RR 1.01, p = 0.77, treatment 1,173 of 5,610 (20.9%), control 1,190 of 5,730 (20.8%).
risk of mechanical ventilation, 18.0% higher, RR 1.18, p = 0.06, treatment 259 of 3,815 (6.8%), control 228 of 3,962 (5.8%).
risk of death/intubation, 2.0% higher, RR 1.02, p = 0.47, treatment 1,344 of 5,342 (25.2%), control 1,343 of 5,469 (24.6%).
risk of no hospital discharge, 2.0% higher, RR 1.02, p = 0.44, treatment 1,709 of 5,610 (30.5%), control 1,698 of 5,730 (29.6%), inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Recovery Collaborative Group et al., 18 May 2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, 35 authors, study period 27 November, 2020 - 4 March, 2021, average treatment delay 9.0 days, dosage 1.5mg day 1, 1mg days 2-10, dose for days 2-10 halved for certain patients, trial NCT04381936 (history) (RECOVERY).
This PaperColchicineAll
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Prof Peter W Horby, Martin J Landray, Collaborative Group, Mark Campbell, Enti Spata, Jonathan R Emberson, Natalie Staplin, Guilherme Pessoa-Amorim, Leon Peto, Martin Wiselka, Laura Wiffen, Simon Tiberi, Ben Caplin, Caroline Wroe, Christopher Green, Paul Hine, Benjamin Prudon, Tina George, Andrew J Wight, Kenneth Baillie, Buddha Basnyat, Maya Buch, Lucy C Chappell, Jeremy Day, Saul N Faust, Raph L Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, W Peter, Mark Horby, Enti Campbell, Marion Spata, Richard Mafham, Martin J Haynes, Landray, Peter Sandercock, Janet Darbyshire, David Demets, Robert Fowler
The Lancet Respiratory Medicine, doi:10.1016/s2213-2600(21)00435-5
Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19. Methods In this streamlined, randomised, controlled, open-label trial, underway at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Patients were eligible for inclusion in the study if they were admitted to hospital with clinically suspected or laboratory confirmed SARS-CoV-2 infection and had no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Eligible and consenting adults were randomly assigned (1:1) to receive either usual standard of care alone (usual care group) or usual standard of care plus colchicine (colchicine group) using web-based simple (unstratified) randomisation with allocation concealment. Participants received colchicine 1 mg after randomisation followed by 500 µg 12 h later and then 500 µg twice a day by mouth or nasogastric tube for 10 days in total or until discharge. Dose frequency was halved for patients receiving a moderate CYP3A4 inhibitor (eg, diltiazem), patients with an estimated glomerular filtration rate of less than 30 mL/min per 1•73m², and those with an estimated bodyweight of less than 70 kg. The primary outcome was 28-day mortality, secondary endpoints included time to discharge, the proportion of patients discharged from hospital within 28 days, and, in patients not on invasive mechanical ventilation at randomisation, a composite endpoint of invasive mechanical ventilation or death. All analyses were by intention-to-treat. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
References
Broz, Dixit, Inflammasomes: mechanism of assembly, regulation and signalling, Nat Rev Immunol
Dalbeth, Lauterio, Wolfe, Mechanism of action of colchicine in the treatment of gout, Clin Ther
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Deftereos, Siasos, Giannopoulos, The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol
Dorward, Russell, Um, Tissue-specific immunopathology in fatal COVID-19, Am J Respir Crit Care Med
Fiolet, Opstal, Mosterd, Efficacy and safety of lowdose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials, Eur Heart J
Horby, Lim, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Horby, Mafham, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Imazio, Brucato, Cemin, A randomized trial of colchicine for acute pericarditis, N Engl J Med
Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, doubleblinded, placebo-controlled clinical trial, RMD Open
Martinez, Celermajer, Patel, The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosisassociated inflammation, Atherosclerosis
Mcelvaney, Mcevoy, Mcelvaney, Characterization of the inflammatory response to severe COVID-19 illness, Am J Respir Crit Care Med
Rodrigues, De Sa, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients; a clinical trial study, Research Square, doi:10.21203/rs.3.rs-69374/v1(preprint
Sterne, Murthy, Diaz, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Tardif, Kouz, Waters, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med
Thwaites, Sevilla Uruchurtu, Siggins, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci Immunol
Wang, Chen, Yang, Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19, J Med Virol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit